patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1 value | histology stringclasses 3 values | stage_at_diagnosis stringclasses 3 values | driver_mutation stringclasses 7 values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2 values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6 values | overall_survival_months float64 4 83 | censored bool 2 classes | msi_status stringclasses 2 values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1 value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_551499 | REC_0000001 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 1.5 | 73 | male | 2 | 49 | 5.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 29.2 | false | MSS | 2026-03-15T05:35:56.823002+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_342890 | REC_0000002 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 7.2 | 74 | female | 3 | 16 | 6 | 6 | alectinib 600 mg BID | 11.9 | false | MSS | 2026-03-15T05:35:56.823622+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_108519 | REC_0000003 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 14.6 | 72 | female | 1 | 15 | 6.5 | 1 | entrectinib 600 mg daily | 7.6 | true | MSI-H | 2026-03-15T05:35:56.824171+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_504292 | REC_0000004 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 5.4 | 63 | male | 1 | 9 | 6 | 1 | entrectinib 600 mg daily | 21.1 | true | MSS | 2026-03-15T05:35:56.824584+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_741181 | REC_0000005 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 11.4 | 72 | female | 1 | 14 | 5.5 | 2 | sotorasib 960 mg daily | 16.2 | true | MSI-H | 2026-03-15T05:35:56.824987+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_120501 | REC_0000006 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 12.3 | 51 | male | 0 | 11 | 5.3 | 8 | sotorasib 960 mg daily | 16.4 | false | MSS | 2026-03-15T05:35:56.825399+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_444069 | REC_0000007 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 33 | 7.1 | 68 | female | 1 | 37 | 5.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 7.7 | true | MSS | 2026-03-15T05:35:56.825738+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_270361 | REC_0000008 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 10.7 | 72 | male | 0 | 13 | 6.4 | 1 | sotorasib 960 mg daily | 19.6 | true | MSI-H | 2026-03-15T05:35:56.826078+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937907 | REC_0000009 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 23 | 5.8 | 64 | male | 0 | 26 | 5.3 | 0 | carboplatin + paclitaxel + pembrolizumab | 57.5 | true | MSS | 2026-03-15T05:35:56.826395+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_827417 | REC_0000010 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 4.3 | 66 | female | 0 | 66 | 7 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.6 | true | MSS | 2026-03-15T05:35:56.826688+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_152339 | REC_0000011 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 17.8 | 72 | female | 2 | 24 | 4.2 | 5 | sotorasib 960 mg daily | 16.9 | true | MSI-H | 2026-03-15T05:35:56.826969+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_547820 | REC_0000012 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 9.2 | 61 | male | 0 | 62 | 3.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 14.7 | false | MSS | 2026-03-15T05:35:56.827288+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_547326 | REC_0000013 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 10.5 | 64 | female | 0 | 20 | 5.2 | 3 | alectinib 600 mg BID | 11.7 | true | MSI-H | 2026-03-15T05:35:56.827575+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275341 | REC_0000014 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 6.4 | 77 | male | 2 | 40 | 6.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.6 | false | MSS | 2026-03-15T05:35:56.828029+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_448140 | REC_0000015 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 14.5 | 77 | female | 2 | 16 | 5.5 | 9 | osimertinib 80 mg daily | 9.2 | false | MSS | 2026-03-15T05:35:56.828441+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_616364 | REC_0000016 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 7.1 | 72 | female | 1 | 20 | 5.8 | 6 | osimertinib 80 mg daily | 11.5 | false | MSS | 2026-03-15T05:35:56.828763+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_637469 | REC_0000017 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 11.6 | 83 | female | 4 | 30 | 6.2 | 1 | osimertinib 80 mg daily | 13.5 | true | MSI-H | 2026-03-15T05:35:56.829039+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690426 | REC_0000018 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 12.7 | 59 | male | 0 | 4 | 3.5 | 1 | sotorasib 960 mg daily | 36.7 | false | MSI-H | 2026-03-15T05:35:56.829298+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_518751 | REC_0000019 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 14.2 | 46 | male | 0 | 19 | 5.1 | 0 | sotorasib 960 mg daily | 21.5 | true | MSI-H | 2026-03-15T05:35:56.829559+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_966331 | REC_0000020 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 11.9 | 82 | male | 2 | 29 | 3.6 | 1 | sotorasib 960 mg daily | 22.6 | false | MSS | 2026-03-15T05:35:56.829799+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_117747 | REC_0000021 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 11.3 | 64 | female | 1 | 16 | 3.6 | 7 | alectinib 600 mg BID | 11.7 | false | MSS | 2026-03-15T05:35:56.830038+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_815454 | REC_0000022 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 1.9 | 66 | female | 1 | 48 | 3.9 | 3 | carboplatin + paclitaxel + pembrolizumab | 12.6 | false | MSS | 2026-03-15T05:35:56.830271+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_384426 | REC_0000023 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 8.4 | 64 | female | 1 | 45 | 6.1 | 8 | carboplatin + paclitaxel + pembrolizumab | 8.6 | true | MSS | 2026-03-15T05:35:56.830509+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_817151 | REC_0000024 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 16.8 | 60 | female | 1 | 15 | 3.8 | 5 | alectinib 600 mg BID | 14.6 | false | MSI-H | 2026-03-15T05:35:56.830748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_786237 | REC_0000025 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 9.2 | 53 | female | 0 | 16 | 5.2 | 8 | alectinib 600 mg BID | 12.8 | false | MSS | 2026-03-15T05:35:56.830980+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_960232 | REC_0000026 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 30 | 4.3 | 68 | male | 0 | 9 | 4 | 0 | carboplatin + paclitaxel + pembrolizumab | 46.9 | false | MSS | 2026-03-15T05:35:56.831216+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626713 | REC_0000027 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 16 | 11.8 | 59 | female | 0 | 16 | 4.8 | 4 | alectinib 600 mg BID | 4 | true | MSS | 2026-03-15T05:35:56.831599+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_876716 | REC_0000028 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 7 | 66 | female | 0 | 37 | 5 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.9 | true | MSS | 2026-03-15T05:35:56.831933+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_318844 | REC_0000029 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 12.1 | 69 | female | 1 | 21 | 5.1 | 4 | alectinib 600 mg BID | 17.7 | true | MSS | 2026-03-15T05:35:56.832418+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_461611 | REC_0000030 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 33 | 8.3 | 65 | female | 0 | 8 | 4.7 | 1 | osimertinib 80 mg daily | 23.4 | false | MSS | 2026-03-15T05:35:56.832811+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_368013 | REC_0000031 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 18 | 1.6 | 56 | male | 0 | 31 | 6.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.6 | true | MSS | 2026-03-15T05:35:56.833185+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334354 | REC_0000032 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 8.2 | 62 | female | 0 | 6 | 6.1 | 7 | osimertinib 80 mg daily | 6.8 | true | MSS | 2026-03-15T05:35:56.833566+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300178 | REC_0000033 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 13.1 | 69 | female | 1 | 21 | 3.4 | 6 | sotorasib 960 mg daily | 15.3 | false | MSS | 2026-03-15T05:35:56.834006+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772619 | REC_0000034 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 10.7 | 70 | female | 2 | 18 | 6.1 | 4 | entrectinib 600 mg daily | 18.7 | false | MSI-H | 2026-03-15T05:35:56.834409+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_351480 | REC_0000035 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 9.9 | 57 | female | 1 | 22 | 6.7 | 4 | alectinib 600 mg BID | 10.8 | false | MSS | 2026-03-15T05:35:56.834844+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_372546 | REC_0000036 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 8.9 | 61 | female | 1 | 1 | 6.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 6 | false | MSS | 2026-03-15T05:35:56.835225+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511458 | REC_0000037 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 5.5 | 72 | female | 0 | 45 | 8.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 18.5 | true | MSS | 2026-03-15T05:35:56.835596+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381340 | REC_0000038 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 13.5 | 73 | male | 4 | 18 | 5.8 | 6 | osimertinib 80 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:56.835979+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_615294 | REC_0000039 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 6.1 | 74 | female | 1 | 21 | 6.2 | 5 | alectinib 600 mg BID | 12.4 | false | MSS | 2026-03-15T05:35:56.836423+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_620719 | REC_0000040 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 15.1 | 73 | female | 1 | 13 | 6.9 | 4 | osimertinib 80 mg daily | 11.4 | false | MSS | 2026-03-15T05:35:56.837041+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_653341 | REC_0000041 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 3 | 74 | female | 2 | 60 | 7 | 2 | carboplatin + paclitaxel + pembrolizumab | 19.3 | false | MSS | 2026-03-15T05:35:56.837472+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_113576 | REC_0000042 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 9.8 | 65 | male | 0 | 19 | 6 | 5 | alectinib 600 mg BID | 18.4 | false | MSS | 2026-03-15T05:35:56.837818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_934874 | REC_0000043 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 12.8 | 62 | male | 0 | 12 | 4.3 | 4 | osimertinib 80 mg daily | 11.5 | true | MSI-H | 2026-03-15T05:35:56.838142+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_380114 | REC_0000044 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 13.1 | 64 | male | 1 | 21 | 5.4 | 3 | sotorasib 960 mg daily | 9.5 | true | MSI-H | 2026-03-15T05:35:56.838462+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_964800 | REC_0000045 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 11.8 | 68 | female | 0 | 10 | 4.9 | 1 | pembrolizumab 200 mg q3w | 17.9 | true | MSS | 2026-03-15T05:35:56.838764+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_676820 | REC_0000046 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 11.7 | 68 | female | 0 | 12 | 6.8 | 6 | alectinib 600 mg BID | 16.4 | true | MSS | 2026-03-15T05:35:56.839086+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_922889 | REC_0000047 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 11.7 | 62 | female | 0 | 14 | 5.5 | 1 | osimertinib 80 mg daily | 24.5 | true | MSI-H | 2026-03-15T05:35:56.839414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_997233 | REC_0000048 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 19 | 7.4 | 60 | female | 0 | 66 | 5.3 | 4 | pembrolizumab 200 mg q3w | 11.9 | true | MSS | 2026-03-15T05:35:56.839749+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_808682 | REC_0000049 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 28 | 12.5 | 51 | male | 0 | 16 | 5.7 | 0 | sotorasib 960 mg daily | 54.8 | true | MSS | 2026-03-15T05:35:56.840164+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_802689 | REC_0000050 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 7 | 80 | female | 2 | 30 | 2 | 0 | carboplatin + paclitaxel + pembrolizumab | 24.3 | true | MSS | 2026-03-15T05:35:56.840538+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865154 | REC_0000051 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 9 | 76 | female | 2 | 17 | 5.9 | 6 | entrectinib 600 mg daily | 8.9 | true | MSS | 2026-03-15T05:35:56.840870+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378114 | REC_0000052 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 33 | 16.9 | 60 | female | 0 | 12 | 4 | 2 | entrectinib 600 mg daily | 17.6 | false | MSI-H | 2026-03-15T05:35:56.841195+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_927515 | REC_0000053 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 18.9 | 73 | female | 1 | 32 | 4.5 | 2 | sotorasib 960 mg daily | 11.2 | false | MSS | 2026-03-15T05:35:56.841595+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_401580 | REC_0000054 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 31 | 6.1 | 54 | male | 0 | 47 | 4.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 25.7 | false | MSS | 2026-03-15T05:35:56.841856+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_601006 | REC_0000055 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 17.9 | 67 | female | 0 | 13 | 2.8 | 3 | pembrolizumab 200 mg q3w | 9.5 | true | MSS | 2026-03-15T05:35:56.842100+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747593 | REC_0000056 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 11.1 | 66 | female | 0 | 17 | 6.5 | 5 | entrectinib 600 mg daily | 10.5 | true | MSS | 2026-03-15T05:35:56.842346+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_316930 | REC_0000057 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 7.5 | 57 | female | 0 | 12 | 6.8 | 1 | entrectinib 600 mg daily | 11 | true | MSS | 2026-03-15T05:35:56.842607+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_682060 | REC_0000058 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 16.5 | 70 | female | 2 | 20 | 5.8 | 0 | entrectinib 600 mg daily | 13.7 | false | MSS | 2026-03-15T05:35:56.842899+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532523 | REC_0000059 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 17.7 | 64 | female | 1 | 20 | 7.1 | 8 | entrectinib 600 mg daily | 6.9 | false | MSI-H | 2026-03-15T05:35:56.843175+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_949900 | REC_0000060 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 12.3 | 70 | female | 2 | 22 | 4.2 | 6 | entrectinib 600 mg daily | 5.6 | false | MSI-H | 2026-03-15T05:35:56.843433+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_613503 | REC_0000061 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 10.3 | 73 | female | 2 | 21 | 5.4 | 4 | sotorasib 960 mg daily | 15.7 | false | MSI-H | 2026-03-15T05:35:56.843671+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_683637 | REC_0000062 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 11.9 | 59 | female | 0 | 18 | 6.2 | 4 | sotorasib 960 mg daily | 17.5 | false | MSI-H | 2026-03-15T05:35:56.843911+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_402727 | REC_0000063 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 15.8 | 82 | female | 1 | 10 | 4.7 | 7 | osimertinib 80 mg daily | 10.8 | true | MSS | 2026-03-15T05:35:56.844195+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_893393 | REC_0000064 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 17 | 70 | female | 2 | 21 | 5 | 8 | alectinib 600 mg BID | 13.8 | false | MSI-H | 2026-03-15T05:35:56.844443+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_496857 | REC_0000065 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 13.4 | 84 | male | 2 | 13 | 6.3 | 5 | alectinib 600 mg BID | 12.2 | false | MSS | 2026-03-15T05:35:56.844681+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_671230 | REC_0000066 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 5.7 | 72 | female | 1 | 26 | 6 | 7 | carboplatin + paclitaxel + pembrolizumab | 8.4 | false | MSS | 2026-03-15T05:35:56.845007+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_647840 | REC_0000067 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 21.4 | 68 | female | 1 | 7 | 5.2 | 2 | osimertinib 80 mg daily | 21.7 | true | MSI-H | 2026-03-15T05:35:56.845248+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931371 | REC_0000068 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 13.5 | 63 | male | 0 | 15 | 3.8 | 2 | alectinib 600 mg BID | 22 | true | MSS | 2026-03-15T05:35:56.845487+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_559788 | REC_0000069 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 11.9 | 48 | male | 0 | 8 | 6.1 | 4 | alectinib 600 mg BID | 13.7 | false | MSI-H | 2026-03-15T05:35:56.845721+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_170136 | REC_0000070 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 13.2 | 69 | female | 0 | 22 | 3.6 | 3 | pembrolizumab 200 mg q3w | 9.6 | false | MSS | 2026-03-15T05:35:56.845951+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_895721 | REC_0000071 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 6.9 | 62 | male | 1 | 27 | 7 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.2 | true | MSS | 2026-03-15T05:35:56.846184+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_880270 | REC_0000072 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 8.4 | 66 | male | 0 | 17 | 5.8 | 3 | pembrolizumab 200 mg q3w | 9.8 | false | MSS | 2026-03-15T05:35:56.846422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_665298 | REC_0000073 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 17.6 | 61 | male | 0 | 18 | 6.4 | 6 | sotorasib 960 mg daily | 17.6 | false | MSI-H | 2026-03-15T05:35:56.846656+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_182781 | REC_0000074 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 23 | 12.7 | 80 | male | 1 | 17 | 6.1 | 0 | sotorasib 960 mg daily | 47.4 | true | MSS | 2026-03-15T05:35:56.846891+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_908058 | REC_0000075 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 3.4 | 56 | female | 1 | 51 | 6.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.6 | false | MSS | 2026-03-15T05:35:56.847125+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_354716 | REC_0000076 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 11.6 | 60 | female | 1 | 24 | 7.3 | 5 | sotorasib 960 mg daily | 18.1 | true | MSI-H | 2026-03-15T05:35:56.847360+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121016 | REC_0000077 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 13.1 | 63 | male | 1 | 2 | 5.6 | 6 | osimertinib 80 mg daily | 13.1 | false | MSS | 2026-03-15T05:35:56.847594+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_176396 | REC_0000078 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 12.7 | 47 | female | 0 | 15 | 5.8 | 4 | osimertinib 80 mg daily | 13 | false | MSS | 2026-03-15T05:35:56.847829+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738160 | REC_0000079 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 5.2 | 55 | female | 0 | 17 | 6.4 | 4 | alectinib 600 mg BID | 8.2 | false | MSS | 2026-03-15T05:35:56.848309+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_808279 | REC_0000080 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 16.4 | 59 | male | 1 | 8 | 5.3 | 8 | osimertinib 80 mg daily | 17.7 | false | MSS | 2026-03-15T05:35:56.848733+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_167673 | REC_0000081 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 31 | 9.8 | 62 | female | 0 | 17 | 5.8 | 7 | pembrolizumab 200 mg q3w | 10.7 | false | MSS | 2026-03-15T05:35:56.849110+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_422291 | REC_0000082 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 5.5 | 60 | male | 1 | 14 | 5.1 | 6 | osimertinib 80 mg daily | 6.9 | false | MSS | 2026-03-15T05:35:56.849477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210028 | REC_0000083 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 34 | 11.6 | 79 | male | 2 | 21 | 7.3 | 3 | osimertinib 80 mg daily | 16.3 | true | MSS | 2026-03-15T05:35:56.849846+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_359788 | REC_0000084 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 5.3 | 72 | female | 1 | 12 | 5.2 | 3 | pembrolizumab 200 mg q3w | 8.4 | false | MSS | 2026-03-15T05:35:56.850168+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_509644 | REC_0000085 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 12.5 | 73 | male | 2 | 15 | 6.3 | 1 | sotorasib 960 mg daily | 14.4 | false | MSS | 2026-03-15T05:35:56.850452+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_199692 | REC_0000086 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 16 | 4.1 | 71 | female | 1 | 54 | 6.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 19.6 | true | MSS | 2026-03-15T05:35:56.850708+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_633195 | REC_0000087 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 8.8 | 66 | female | 1 | 11 | 6.9 | 2 | pembrolizumab 200 mg q3w | 12.7 | true | MSS | 2026-03-15T05:35:56.850985+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590496 | REC_0000088 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 16.9 | 62 | male | 1 | 23 | 5.6 | 5 | alectinib 600 mg BID | 9.1 | false | MSI-H | 2026-03-15T05:35:56.851277+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795703 | REC_0000089 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 15.3 | 70 | male | 1 | 8 | 6.6 | 3 | entrectinib 600 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:56.851568+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_680113 | REC_0000090 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 17 | 75 | male | 2 | 22 | 5.2 | 8 | osimertinib 80 mg daily | 11.1 | false | MSI-H | 2026-03-15T05:35:56.851862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_512814 | REC_0000091 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 19 | 86 | male | 2 | 20 | 7.1 | 5 | alectinib 600 mg BID | 8.5 | false | MSS | 2026-03-15T05:35:56.852219+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_641445 | REC_0000092 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 32 | 12 | 67 | female | 0 | 23 | 6.5 | 2 | osimertinib 80 mg daily | 5.6 | false | MSI-H | 2026-03-15T05:35:56.852665+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_940532 | REC_0000093 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 8.3 | 74 | female | 1 | 1 | 5.3 | 7 | osimertinib 80 mg daily | 13.3 | false | MSS | 2026-03-15T05:35:56.852970+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_286822 | REC_0000094 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 15.7 | 71 | female | 2 | 25 | 6.2 | 1 | alectinib 600 mg BID | 19.8 | false | MSI-H | 2026-03-15T05:35:56.853234+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_400252 | REC_0000095 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 13.1 | 62 | male | 1 | 13 | 3.6 | 6 | entrectinib 600 mg daily | 15.3 | false | MSI-H | 2026-03-15T05:35:56.853480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_647930 | REC_0000096 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 14.1 | 67 | male | 0 | 15 | 6.1 | 5 | sotorasib 960 mg daily | 10.1 | false | MSS | 2026-03-15T05:35:56.853727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_307184 | REC_0000097 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 28 | 7.1 | 58 | male | 1 | 52 | 2.9 | 0 | carboplatin + paclitaxel + pembrolizumab | 32.8 | false | MSS | 2026-03-15T05:35:56.853974+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_621594 | REC_0000098 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 11.4 | 54 | male | 0 | 12 | 4.7 | 4 | entrectinib 600 mg daily | 16.9 | true | MSS | 2026-03-15T05:35:56.854229+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_385761 | REC_0000099 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 4.2 | 70 | female | 0 | 63 | 6.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.3 | true | MSS | 2026-03-15T05:35:56.854485+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_976965 | REC_0000100 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 17.2 | 61 | female | 0 | 8 | 4.3 | 6 | osimertinib 80 mg daily | 14.1 | true | MSI-H | 2026-03-15T05:35:56.854772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.